Experimental immune therapy targets Tough-to-Treat blood cancer
Disease control
Terminated
This study tested an experimental immune therapy called CAR-T cells in Chinese patients with multiple myeloma that had returned or stopped responding to standard treatments. Researchers collected and reprogrammed patients' own immune cells to attack cancer cells, then infused the…
Phase: PHASE2 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC